Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Knowing when to sell index funds in a recession helps protect capital and rebalance for future growth. This intro offers timing considerations.
15,106 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Oklo has shed 28% over the past month as investors rotate away from pre-revenue nuclear developers. Utilities remain ...
Oracle’s shares have fallen sharply this year, leaving investors wondering if the decline creates a buying opportunit...
A renowned market thinker known for optimism outlines a three-phase market path, warning of a near-term correction or...
A $10,000 investment in Asia’s biggest stocks grew to $15,267 by June 3, 2026, outpacing most U.S. large caps and hig...
Bitcoin trades near $63,000 as pardon discussions around Sam Bankman-Fried surface in crypto news. A $32 million hack...
June market swings have hit chip names hard, but the smarter money is shifting toward a single AI-dominant tech heavy...
Broadcom just dropped a major update that could reshape its margin trajectory and investor strategy. This guide break...
CEO confidence dropped to a negative outlook in Q2 2026, suggesting the economy may worsen over the next six months. ...
In a hypothetical mid-June scenario, SpaceX launches a historic $1.75 trillion IPO, raising $85.7 billion and closing...
A chip-focused fund jumps roughly 80% in 2026, signaling investors are seeking broader exposure to AI infrastructure ...
The 2027 COLA could lift benefits, but rising Medicare costs and hold-harmless rules mean many retirees may see littl...